Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, will present new data from across its portfolio and pipeline at the 2026 American Association ...
These results highlight the need for clinicians to investigate potential high-grade lymphoid malignancies in cases of refractory CAD.
These results highlight the need for clinicians to investigate potential high-grade lymphoid malignancies in cases of refractory CAD.
The following is a repost from Facebook by Professor Takayoshi Shimohata, Department of Neurology, Gifu University Graduate ...
Trio of Challengers produce career highs in another 4A top-10 triumph; Ashland wins home opener Cascade Christian promised a ...
The publication follows the FDA's recent label expansion of EMPAVELI for patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative ...
EMPAVELI significantly reduced proteinuria in adolescents with kidney diseases, following an FDA label expansion for this age group. Biogen has announced that adolescents treated with EMPAVELI® ...
Biogen published results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology ...
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved ...
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo ; EMPAVELI is the only approved treatment for adolescents with C3G and ...
The US actor Sydney Sweeney is facing a backlash from female Olympians and other athletes, who have accused her of demeaning and sexualising women’s sports by appearing in a controversial advert for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results